c-Myc-Inhibitors-Modulators-MCE

1、 HYPERLINK https:/www.MedChemE/Targets/c-Myc.html c-MycMycThe transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes ofthe c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthes

2、is, cell adhesion, andmicro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS)cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerizationwith its activation

3、 partner Max.c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptionalcoregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion,or chromosomal translocation is asso

4、ciated with tumorigenesis. c-Myc has been identified as a highly promising target for cancertherapy.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/c-Myc.html c-Myc HYPERLINK https:/www.MedChemE/Targets/c-Myc.html HYPERLINK https:/www.MedChemE/Targets/c-Myc.html Inhibitors HYPERLINK https:/www.

5、MedChemE/10058-F4.html 10058-F4 HYPERLINK https:/www.MedChemE/10058-F4.html HYPERLINK https:/www.MedChemE/10074-a4.html 10074-A4Cat. No.: HY-12702 Cat. No.: HY-12412910058-F4 is a c-Myc inhibitor that preventsc-Myc-Max dimerization and transactivation ofc-Myc target gene expression.10074-A4 is a c-M

6、yc inhibitor. 10074-A4 could bindto c-Myc at different sites along the370-409peptide chain. 10074-A4 has anticancer effects.Purity: 99.77%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mgPurity: 98.03%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLIN

7、K https:/www.MedChemE/10074-G5.html 10074-G5Cat. No.: HY-100996 HYPERLINK https:/www.MedChemE/APTO-253.html APTO-253(LOR-253; LT-253) Cat. No.: HY-1629110074-G5 is an inhibitor of c-Myc-Maxdimerization with an IC of 146 M.50APTO-253 (LOR-253) is a small molecule thatinhibits c-Myc expression, stabil

8、izesG-quadruplex DNA, and induces cell cycle arrestand apoptosis in acute myeloid leukemia cells.Purity: 96.81%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98.15%Clinical Data: Phase 1Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/ww

9、w.MedChemE/brd4-inhibitor-18.html BRD4 HYPERLINK https:/www.MedChemE/brd4-inhibitor-18.html HYPERLINK https:/www.MedChemE/brd4-inhibitor-18.html Inhibitor-18 HYPERLINK https:/www.MedChemE/brd4-inhibitor-18.html HYPERLINK https:/www.MedChemE/btynb.html BTYNBCat. No.: HY-146660 Cat. No.: HY-124447BRD4

10、 Inhibitor-18 is a highly potent BRD4inhibitor with an IC value of 110 nM. BRD450Inhibitor-18 has a hydrophobic acetylcyclopentanylside chain. BRD4 Inhibitor-18 can significantlysuppress the proliferation of MV-4-11 cells withhigh BRD4 level.BTYNB is a potent and selective inhibitor ofIMP1 binding t

11、o c-Myc mRNA (IC =5 M). BTYNB50exhibits selectivity and effectiveness againstIMP1-postive cancer cell lines. BTYNB can be usedfor cancer research.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.0%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 m

12、g HYPERLINK https:/www.MedChemE/c-myc-inhibitor-4.html c-Myc HYPERLINK https:/www.MedChemE/c-myc-inhibitor-4.html HYPERLINK https:/www.MedChemE/c-myc-inhibitor-4.html inhibitor HYPERLINK https:/www.MedChemE/c-myc-inhibitor-4.html HYPERLINK https:/www.MedChemE/c-myc-inhibitor-4.html 4 HYPERLINK https

13、:/www.MedChemE/c-myc-inhibitor-4.html HYPERLINK https:/www.MedChemE/c-myc-inhibitor-5.html c-Myc HYPERLINK https:/www.MedChemE/c-myc-inhibitor-5.html HYPERLINK https:/www.MedChemE/c-myc-inhibitor-5.html inhibitor HYPERLINK https:/www.MedChemE/c-myc-inhibitor-5.html HYPERLINK https:/www.MedChemE/c-my

14、c-inhibitor-5.html 5Cat. No.: HY-139885 Cat. No.: HY-145843c-Myc inhibitor 4 is a potent, orally bioavailablec-MYC-reducing compound.c-Myc inhibitor 5 (DA3) is a fluorescent, longchain-bridged bispurine that selectively targetsthe c-MYC G-quadruplex (K of 16 M). c-MycDinhibitor 5 shows inhibition on

15、 c-MYC expressionrather than other G4-driven oncogenes.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/cmld010509.html CMLD010509 HYPERLINK https:/www.MedChemE/cmld010509.html HYPERLINK h

16、ttps:/www.MedChemE/en4.html EN4(SDS-1-021) Cat. No.: HY-119271Cat. No.: HY-134761CMLD010509 (SDS-1-021) is a highly specificinhibitor of the oncogenic translation programsupporting multiple myeloma (MM)-including keyoncoproteins such as MYC, MDM2, CCND1, MAF, andMCL-1.EN4 is a covalent ligand that t

17、argets cysteine 171(C171) of MYC. EN4 is selective for c-MYCover N-MYC and L-MYC. EN4 inhibits MYCtranscriptional activity, downregulates MYCtargets, and impairs tumorigenesis.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 96.05%Clinical Data: No Development ReportedSize: 1

18、0 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/hnrnpk-in-1.html hnRNPK-IN-1 HYPERLINK https:/www.MedChemE/hnrnpk-in-1.html HYPERLINK https:/www.MedChemE/ires-c11.html IRES-C11Cat. No.: HY-135691 Cat. No.: HY-124811

19、hnRNPK-IN-1 is a heterogeneous nuclearribonucleoprotein K (hnRNPK) binding ligand withK values of 4.6 M and 2.6 M measured with SPRdand MST, respectively. hnRNPK-IN-1 inhibits c-myctranscription by disrupting the binding of hnRNPKand c-myc promoter.IRES-C11 is a spectfic c-MYC internal ribosomeentry

20、 site (IRES) translation inhibitor. IRES-C11blocks the interaction of a requisite c-MYC IREStrans-acting factor, heterogeneous nuclearribonucleoprotein A1, with its IRES. IRES-C11 doesnot inhibits BAG-1, XIAP and p53 IRESes.Purity: 97.11%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg

21、, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/IZCZ-3.html IZCZ-3 HYPERLINK https:/www.MedChemE/IZCZ-3.html HYPERLINK https:/www.MedChemE/KJ-Pyr-9.html KJ HYPERLINK https:/www.MedChemE/KJ-Pyr-9.html HYPERLINK https:/www.MedChemE/KJ-Pyr-

22、9.html Pyr HYPERLINK https:/www.MedChemE/KJ-Pyr-9.html HYPERLINK https:/www.MedChemE/KJ-Pyr-9.html 9Cat. No.: HY-111411 Cat. No.: HY-19735IZCZ-3 is a potent c-MYC transcription inhibitorwith antitumor activity.KJ Pyr 9 is an inhibitor of MYC with a K ofd6.5 nM in in vitro assay.Purity: 99.45%Clinica

23、l Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.29%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/KSI-3716.html KSI-3716 HYPERLINK https:/www.MedChemE/KSI-3716.html HYPERLINK https:/www.MedChemE/lusianthridin

24、.html LusianthridinCat. No.: HY-12703 Cat. No.: HY-121418KSI-3716 is a potent c-Myc inhibitor thatblocks c-MYC/MAX binding to target gene promoters.KSI-3716 is an effective intravesical chemotherapyagent for bladder cancer.Lusianthridin, a pure compound from Dendrobiumvenustum, have an anti-migrator

25、y effect.Lusianthridin enhances c-Myc degradation throughthe inhibition of Src-STAT3 signaling.Purity: 98.55%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg HYPERLINK https:/www.MedChemE/ML327

26、.html ML327 HYPERLINK https:/www.MedChemE/ML327.html HYPERLINK https:/www.MedChemE/myc-in-2.html MYC-IN-2Cat. No.: HY-103038 Cat. No.: HY-141666ML327 is a blocker of MYC which can alsode-repress E-cadherin transcription and reverseEpithelial-to-Mesenchymal Transition (EMT).MYC-IN-2 is a MYC protein-

27、protein inhibitor.MYC-IN-2 can be used for the research of cancer.Purity: 98.19%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 100 mg HYPERLINK https:/www.MedChemE/myci361.html MYCi361 HYPERLINK ht

28、tps:/www.MedChemE/myci361.html HYPERLINK https:/www.MedChemE/mycmi-6.html MYCMI-6(NUCC-0196361) Cat. No.: HY-129600 (NSC354961) Cat. No.: HY-124675MYCi361 (NUCC-0196361) is a MYC inhibitor withthe K of 3.2 M for binding to MYC. MYCi361d(NUCC-0196361) suppresses tumor growth andenhances anti-PD1 immu

29、notherapy.MYCMI-6 (NSC354961) is a potent and selectiveendogenous MYC:MAX protein interactionsinhibitor. MYCMI-6 blocks MYC-driven transcriptionand binds selectively to the MYC bHLHZip domainwith a K of 1.6M.dPurity: 99.42%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 5

30、0 mg, 100 mgPurity: 95.95%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/Mycro_3.html Mycro HYPERLINK https:/www.MedChemE/Mycro_3.html HYPERLINK https:/www.MedChemE/Mycro_3.html 3 HYPERLINK https:/www.MedChemE/Mycro_3.html HYPERLINK

31、 https:/www.MedChemE/ny2267.html NY2267Cat. No.: HY-100669 Cat. No.: HY-134975Mycro 3 is a potent and selective inhibitor ofMyc-associated factor X (MAX) dimerization.Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3could be used for the research of pancreaticcancer.NY2267 is a disruptor of Myc-Max interaction,with an IC of 36.5 M. NY2267